Approximately 65% of renal cell carcinomas (RCC) are diagnosed at a localized stage. We investigated the chromosome 5q gain impact on disease-free survival (DFS) in RCC patients. Overall, 676 patients with stages 1-2 RCC and having cytogenetic analysis were included. Gain of 5q was observed in 108 patients, more frequently in clear cell (ccRCC) than non-clear cell tumors. Gain of 5q is likely an independent prognostic factor since the concerned patients had a decreased recurrence risk in stages 1-2 RCC, confirmed in multivariable analysis. Detecting 5q gain could enhance recurrence risk assessment, allowing tailored post-surgery surveillance, and reducing unnecessary treatments.
Cancer investigation. 2024 Feb 05 [Epub ahead of print]
Cedric Lebacle, Aydin Pooli, Brian Shuch, Nagesh Rao, Karim Chamie, Nils Kroeger, Izak Faiena, Sandy Liu, Erika L Wood, Arie Belldegrun, Alexandra Drakaki, Allan J Pantuck
Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USA., Department of Pathology and Lab Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA., Department of Urology, University Medicine Greifswald, Greifswald, Germany., Department of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, California, USA.